An investigator Initiated phase II trial to Evaluate 48-week treatment with GKT831 in patients with type 1 diabetes and kidney disease.
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs GKT 831 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 28 Jun 2017 According to a GenKyoTex media release, Professor Mark Cooper (Head of the Department of Diabetes at Monash University) and Professor Jonathan Shaw (Deputy Director, at the Baker Heart and Diabetes Institute in Melbourne) will lead the conduct of trial. This study will be based at the Baker institute and is financially supported by JDRF Australia.
- 28 Jun 2017 According to a GenKyoTex media release, company expects to begin patient enrollment during the second half of 2017.